Skip to main content
SpringerLink
Log in

Adverse events with nivolumab plus ipilimumab

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Phase Ib: CA209−004, NCT01024231; Phase II: CheckMate 069; NCT10224231; Phase III: CheckMate 067, NCT01844505.

Reference

  • Sznol M, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology : 15 Sep 2017. Available from: URL: http://doi.org/10.1200/JCO.2016.72.1167

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adverse events with nivolumab plus ipilimumab. Reactions Weekly 1671, 8 (2017). https://doi.org/10.1007/s40278-017-36442-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-36442-8

Search

Navigation